The curative effect of bisphosphonates on breast cancer is also mentioned in recent publications [15] discussing potential options for the treatment of lysyl oxidase positive, estrogen receptor negative (LOX+, ER−) breast cancer patients. This evidence concerns the gene ESR1 and breast carcinoma.